The present study was designed to investigate the effect of insulin on insulin resistance (IR), plasma adiponectin level and expression of adiponectin receptors 1 (AdipoR1) in obese and streptozotocin-induced type 2 diabetic rats. Male Sprague-Dowley rats were randomized to control group and 3 obese experimental groups. Type 2 diabetic mellitus was induced in the 3 rd and 4 th experimental groups by given 30 mg/kg of a single dose streptozotocin via intraperitoneal injection (i.p.). Fourth group was treated with i.p. 1 IU insulin/kg/day for 6 days before end of the experiment which lasts for 8 weeks while same amount of normal saline was i.p. given to other group. At the end of the study (8 weeks), plasma levels of adiponectin, triglycerides (TG), cholesterol, fasting blood glucose and insulin were measured. Obesity index (OI) and IR were calculated. AdipoR1 mRNA levels in the soleus muscle tissue were semi-quantitated. Hyperlipidemia, hyperinsulinemia and hyperglycemia were observed in both obese and diabetic rats, which were accompanied by hypoadiponectinemia and down regulation of AdipoR1 expression as compared to the control rats. Adiponectin was negatively correlated with all the biochemical parameters assessed. Insulin treatment significantly improved these metabolic abnormalities and effectively restored adiponectin and AdipoR1 to the control level. In conclusion, adiponectin and its receptor-associated cascade may be aberrantly regulated in both obesity and type 2 diabetes and targeting adiponectin and its receptors may offer a novel therapy against obesity and type 2 diabetes.
INTRODUCTION
White adipose tissue has been increasingly recognized as an important endocrine organ that secretes a number of biologically active adipocytokines including adiponectin. 1) Adiponectin mediates its effects through at least three cell membrane receptors: adiponectin receptor-1 (AdipoR1) expressed abundantly in skeletal muscles, AdipoR2 expressed abundantly in the liver, and recently identified T-cadherin expressed primarily in vascular endothelial and smooth muscle cells. These re- * To whom correspondence should be addressed: Department of Physiology, College of Medicine, King Khalid University, Abha 61421, P.O. Box 641 Saudi Arabia. Tel.: +966-7241-7879; Fax: +966-7241-8364; E-mail: fahaid999@yahoo.com ceptors activate adenosine mono phosphate protein kinase (AMPK) and peroxisome proliferatoractivated receptor-α (PPAR-α) upon adiponectin binding, thereby leading to fatty acid oxidation and glucose uptake. 2) Circulating adiponectin level (1.9-17.0 µg/ml) in healthy adults accounts for 0.01% of total plasma proteins. 3, 4) Many factors affect plasma adiponectin concentration. Among these, circadian rhythm has been demonstrated to regulate diurnal and pulsatile secretion of adiponectin in humans; adiponectin peaks in the morning and decreases at night. 5) Moreover, plasma adiponectin level is higher in human and rodent females than in males, suggesting that sex hormones may regulate the production of adiponectin. 6, 7) Another important category of regulators of adiponectin expression and secretion are dietary factors. Fish oils and linoleic acid have also been demonstrated to be able to increase plasma adiponectin level, 8, 9) which is consistent with the fact/observation that intake of these substances results in enhanced protection against the development of diabetic mellitus (DM). In contrast, carbohydrate-rich and high-fat diets appear to decrease plasma adiponectin level. 10) In addition, plasma adiponectin concentration is negatively correlated with body mass index (BMI), insulin resistance (IR), triglyceride (TG) and low density lipoproteins (LDL) and positively correlated with high density lipoproteins (HDL). 11) Accordingly, plasma adiponectin concentration has also been found to be high in thin individuals, inflammation, and in type 1 DM, and low in type 2 DM, lipodystrophy and in obese individuals. 12) Given the importance of adiponectin and its receptors in fat and glucose metabolism as well as in the pathogenesis, it is warranted to have a better understanding of the regulation of adiponectin and its receptors, which may lead to development of novel preventive and therapeutic strategies for control of DM and metabolic syndrome. 13) To this end, the present study was conducted to assess the possible contribution of adiponectin in amelioration of lipid profile and IR, the metabolic abnormalities (hyperlipidemia, hyperinsulinemia and hyperglycemia) in obese and its link to the induced-type 2 diabetes in rats. In addition, the effect of insulin on adiponectin and its receptor expression was also evaluated.
METHODS

Chemicals --Streptozotocin
(Trade name Zanosar) was purchased from Sigma Chemical Company (St. Louis, MO, U.S.A.). The drug was dissolved in 0.1 M sodium citrate (pH 4.5). Long acting protamine zinc insulin (PZI), a premixed suspension of 30% soluble crystalline insulin and 70% isophan insulin, 14) was purchased from Nile Company (Cairo, Egypt). Animals --Forty male Sprague-Dowley rats, 6 weeks old and 145-200 g in body weight, were used. They were kept at 22 ± 1 • C in a 12 hr darklight cycle in the Animal Center of Kasr Al-Aini Faculty/School of Medicine, Cairo University, with free access to food and water. Animals were randomly divided into 4 groups (n = 10, control, obese, type 2 DM, type 2 DM with insulin treatment). Animals in the control group were fed with a standard rat chow composed of: 60% soya bean, gelatin, corn powder, 3.3% crude fibers, 21.2% crude protein, 3.2% crude oil, 12.3% fish and bone powder, vitamins and minerals. Total calorie 30 kcal/kg, while obesity was induced in the other three groups by feeding them with a high-fat diet (35 g of lard per 110 g of above rat chow) for 8 weeks. Type 2 DM was induced in the 3 rd and 4 th group via intra-peritoneal (i.p.) single dose injection of 30 mg streptozotocin/kg. Fourth group was treated with i.p. 1 IU insulin/kg/day for 6 days before the end of the experiment which lasts for 8 weeks while other groups were i.p. treated with same amount of normal saline. Verification of DM --DM was verified 5 days after treatment by measuring blood glucose levels following overnight fasting with the use of glucose oxidase reagent strips (LifeScan, Milpitas, CA, U.S.A.). Rats having blood glucose level ≥ 200 mg/dl were considered diabetic. 15) The experiments were conducted in accordance with Ethical Guidelines for investigations of laboratory animals and were approved by the Ethical Committee of Physiology Department at Kasr AlAini Faculty of Medicine, Cairo University. Laboratory Analyses of Blood Samples --At the end of the 8 week study, animals were fasted overnight and retro-orbital blood samples were obtained using heparinized capillary tubes under pentobarbital (40 mg/kg) anesthesia. Plasma was prepared and stored at −70 • C until analyses.
Plasma insulin concentration was measured by enzyme immunoassay using a rat insulin ELISA kit (Linco Research, MO, U.S.A.) according to the manufacturer's instructions. Plasma glucose concentration was determined using a kit from Diamond Diagnostics as previously described by Trinder. 16) Plasma TG was assayed by the method previously described by Wahlefeld, 17) using a TG quantification kit from BioVision Research. Plasma cholesterol was assayed as previously described by Sundvall, 18) using a cholesterol assay kit BioAssay Systems. Adiponectin concentration was determined by ELISA using a rat adiponectin ELISA kit from Linco Research as instructed by the manufacturer. Calculation of Obesity Index (OI) --At the end of the designated treatments (8 weeks), animals were weighted and the naso-anal length was measured in cm as previously described. 19 Figure 1 shows OI in the control and experimental groups. The OI in the control group was 28.9 ± 0.42 and it increases significantly to 34.4 ± 3.9 and to 33.3 ± 4.6 in the obese and diabetic group respectively. However, in rats that daily received 1 IU/kg of insulin; OI decrease was significant compared with the 3 rd group. Table 1 shows Changes in blood biochemical parameters in control and experimental groups. As compare to control; TG, cholesterol, glucose and insulin were significantly increased in obese and diabetic group rat. Also, there was a significant decrease in the concentration of adiponectin. However, treatment of diabetic group with insulin ameliorated these deleterious effects. Figure 2 shows Changes in AdipoR1 mRNA levels (µ/gm tissue) in control and experimental groups. This was 0.33 ± 0.06 in control group and it decrease significantly to 0.16 ± 0.04 and to 0.18 ± 0.03 in the obese and diabetic group respectively. However, in diabetic rats that daily received 1 IU/kg/ of insulin; AdipoR1 mRNA was significantly increased by 61% as compared to diabetic group.
RESULTS
Changes in OI
Changes in Blood Biochemical Parameters
Changes in AdipoR1 mRNA Levels
Correlation between Plasma Adiponectin and AdipoR1
On reviewing the results of correlation to identify factors most strongly correlated with fasting plasma adiponectin concentration and AdipoR1 expression in skeletal muscle, the present study revealed that plasma adiponectin and AdipoR1 were significantly correlated negatively with the following parameters: BMI, fasting plasma total cholesterol (TC), TG, insulin, glucose levels, and HOMA-IR. Interestingly, the correlation between AdipoR1 
Fig. 2. AdipoR1 in Control Rats and 3 Experimental Rat Groups
Values (µG/mg tissue) are given as mean ± S.D. and are statistically significant at p < 0.05. * : Significant compared with the control group. &: Significant compared with diabetic group. and adiponectin hormone was significantly positive (Table 2) .
DISCUSSION
In this study we showed that high fat diet caused significant metabolic changes, as compared to the standard laboratory chow. These metabolic changes included an increase in OI, hyperlipidemia, hyperinsulinemia and hyperglycemia, which consequently induced increased IR. In addition, these metabolic changes were accompanied by hypoadiponectinemia and down regulation of AdipoR1 expression in skeletal muscles.
It has been hypothesized that in the steady state, adiponectin level is lower, but its receptors level is higher in obese people than in control subjects so that the high levels of AdipoR1 IR can be compensated in obese subjects. 23) Moreover, plasma adiponectin level is inversely correlated to mRNA expression of AdipoR1; the lower the adiponectin plasma level, the higher the expression of the receptors would be. Nevertheless, some other authors suggest that changes in AdipoR1 expression do not always parallel changes in total plasma adiponectin levels. 24) In this study we demonstrated that levels of cholesterol, TG and OI were negatively correlated with adiponectin and AdipoR1 expression in skeletal muscles of obese rats. We also showed a positive correlation between plasma adiponectin and AdipoR1 expression.
The discrepancy between our results and the observations reported in the literature might be due to the difference in the time length of experiments. Our study only lasted 8 weeks, which might not be long enough for the animals to reach a steady state.
Insulin treatment is among the alternative strategies designed to manage type 2 DM and it results in improvement of glycemic control, insulin synthesis and secretion by β-cells. 25) Insulin therapy decreases hepatic glucose output and improves peripheral glucose uptake and may also improve IR. 26) In our study, insulin treatment resulted in an improvement in IR as manifested by decreasing the fasting plasma lipids, insulin and glucose levels as compared to untreated diabetic group. Insulin also effectively brought both adiponectin and AdipoR1 back to the control levels. This mimics the effect of insulin therapy in humans demonstrated by Langouche 27) who observed that insulin therapy increased circulating adiponectin level, normalized the elevated serum C-peptide level and decreased IR by increasing the metabolic insulin signal in human skeletal muscles. It has been shown that administration of insulin to type 2 DM rats noticeably improved the insulin content of β-cells, with a slight reduction in fasting blood glucose and TG as compared to an untreated diabetic group. 25) Despite the significant reduction in glucose level and improvement of IR in insulin-treated diabetic rats as compared to the untreated diabetic rats in our study, the insulin treatment partially restored the glucose level in comparison to the saline controls. Our results may be explained by the work of Mason 28) who reported that insulin treatment by an i.p. route normalized the elevated glucose production in streptozotocin-induced diabetic type 2 rats, while insulin delivered by a subcutaneous route only partially normalized it. In addition, the discrepancies between our results and those reported in the literature may also be attributed to different dose of insulin (once instead of twice/day) and short duration of treatment (6 days) applied in our study.
Both obese rats and streptozotocin-induced type 2 diabetic rats had developed similar metabolic abnormalities and increased IR in association with hypoadiponectinemia and down regulation of AdipoR1 expression in skeletal muscles in our study. All these metabolic changes may suggest a link between obesity and type 2 diabetes. Our study also showed that administration of insulin resulted in an increase in both plasma levels of adiponectin and AdipoR1 expression in skeletal muscles. There is a possibility that the improvement in the metabolism containing glucose levels by insulin may induce the restore of adiponectin and AdipoR1. Adiponectin may play a causative role in the development of insulin resistance and the metabolic syndrome. Alternatively, adiponectin secretion may be regulated by insulin, and, therefore, circulating levels may be a marker of insulin resistance and angiopathy, but not a causal factor. There is evidence to suggest that adiponectin is an important contributor to insulin resistance and the metabolic syndrome. 29) Therefore, adiponectin and its receptors may offer a novel therapy against obesity and type 2 diabetes.
